Article

A call for a global ‘bigger’ data approach to Alzheimer disease

The use case of an Alzheimer's disease data repository

Read more

Clinical trials for Alzheimer’s drugs have an exceptionally high failure rate, discouraging investment in the field. Drug developers need to more effectively harness existing and emerging data and digital technologies to improve the likelihood of success.

Authors:

Chief Development Officer

Want to learn more about Worldwide Clinical Trials?